newsfilter
← Latest News
Business Wire·

AlloVir Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study In Oral Presentation at the 64th ASH Annual Meeting and Exposition

23 of 26 (88%) patients remained free of clinically significant infections caused by any of six common viruses that posoleucel targets through the Week 14 primary endpoint 3 of 26 (12%) patients had clinically